WORCESTER, Mass.--(BUSINESS WIRE)--Agilux Laboratories, Inc. a leading provider of DMPK discovery and development services, is pleased to announce that it is now offering MDCK/MDCK-MDR1 assays, in addition to the existing Caco-2 assays, for assessing the membrane permeability properties of early drug discovery compounds. These permeability assays are part of their extensive suite of ADMET in vitro assay services. Caco-2 assays are used to predict intestinal absorption and also potential efflux by transporters, including P-glycoprotein (Pgp). Likewise, MDCK cells transfected with human MDR1 (Pgp) are useful for assessing candidate compounds for potential as a Pgp substrate or inhibitor, as well as blood-brain-barrier penetration. These assays have been extensively evaluated and qualified to assure their optimum performance and reliability.
Our comprehensive suite of fast turnaround discovery services, including in vitro ADMET assays, in vivo oncology, in vivo PK with large and small molecule discovery bioanalytical services are routinely employed in lead identification, optimization and candidate selection by our clients.
“Agilux Laboratories is excited to add these assays to further broaden the comprehensive suite of discovery services offered to our clients,” said Steve Guyan, Vice President of Sales and Marketing. “As with all our other discovery services, we have an experienced team who pay close attention to the details who are focused upon providing the highest quality data within the timelines necessitated by our clients’ research needs.” Adrian Sheldon, Ph.D., Associate Director of the in vitro Metabolism group, states “For both Caco-2 and the MDCK/MDCK-MDR1 assays, workflows have been designed to enable great flexibility for our clients, and we can routinely accommodate drop-in requests with no notice and data turnaround of three days.”
About Agilux Laboratories, Inc.
With a passion for exceptional client service and a focus on building long term relationships, Agilux Laboratories, Inc., has become one of the fastest growing contract research organizations (CRO) offering a comprehensive suite of DMPK, pharmacology and bioanalytical services.
With discovery fit-for-purpose services and processes designed and built for agility and speed, Agilux routinely exceed their pharmaceutical, biotech and medical device client’s timeline expectations for drug discovery and development studies. Agilux delivers “Better Data Faster.”